Brugts, J. J.
Veenis, J. F.
Radhoe, S. P.
Linssen, G. C. M.
van Gent, M.
Borleffs, C. J. W.
van Ramshorst, J.
van Pol, P.
Tukkie, R.
Spee, R. F.
Emans, M. E.
Kok, W.
van Halm, V.
Handoko, L.
Beeres, S. L. M. A.
Post, M. C.
Boersma, E.
Lenzen, M. J.
Manintveld, O. C.
Koffijberg, H.
van Baal, P.
Versteegh, M.
Smilde, T. D.
van Heerebeek, L.
Rienstra, M.
Mosterd, A.
Delnoy, P. P. H.
Asselbergs, F. W.
Brunner-La Rocca, H. P.
de Boer, R. A.
Article History
First Online: 27 November 2019
Conflict of interest
: J.J. Brugts has received speaker fees from Abbott and Vifor. M. Versteegh is a member of the EuroQoL research foundation. W. Kok: has received speaker fees from Novartis and Roche. S.L.M.A. Beeres is a medical advisor at the National Health Care Institute (Zorginstituut Nederland). L. Handoko has received an educational grant from Novartis (<5kE), as well as speaker’s fees from Novartis, Boehringer-Ingelheimand Vifor Pharma. F.W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. The UMCG, which employs R.A. de Boer, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk and Roche. R.A. de Boer is a minority shareholder of scPharmaceuticals and has received personal fees from Abbott, AstraZeneca, MandalMed Inc. and Novartis. J.F. Veenis, S.P. Radhoe, G.C.M. Linssen; M. van Gent, C.J.W. Borleffs, J. van Ramshorst, P. van Pol, R. Tukkie, R.F. Spee, M.E. Emans, V. van Halm, M.C. Post, E. Boersma, M.J. Lenzen, O.C. Manintveld, H. Koffijberg, P. van Baal, T.D. Smilde, L. van Heerebeek, M. Rienstra, A. Mosterd, P.P.H. Delnoy and H.P. Brunner-La Rocca declare that they have no competing interests.